Raymond James Financial Inc. Makes New Investment in Vaxcyte, Inc. (NASDAQ:PCVX)

Raymond James Financial Inc. acquired a new position in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 264,704 shares of the company's stock, valued at approximately $21,669,000. Raymond James Financial Inc. owned approximately 0.21% of Vaxcyte as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Whipplewood Advisors LLC purchased a new position in shares of Vaxcyte during the fourth quarter valued at approximately $28,000. Smartleaf Asset Management LLC raised its stake in Vaxcyte by 188.4% during the 4th quarter. Smartleaf Asset Management LLC now owns 398 shares of the company's stock valued at $33,000 after buying an additional 260 shares during the last quarter. National Bank of Canada FI bought a new position in shares of Vaxcyte during the 4th quarter valued at $41,000. Blue Trust Inc. boosted its stake in shares of Vaxcyte by 100.0% in the 4th quarter. Blue Trust Inc. now owns 742 shares of the company's stock worth $61,000 after buying an additional 371 shares during the last quarter. Finally, Assetmark Inc. grew its holdings in shares of Vaxcyte by 77,500.0% in the fourth quarter. Assetmark Inc. now owns 776 shares of the company's stock worth $64,000 after acquiring an additional 775 shares during the period. Institutional investors own 96.78% of the company's stock.

Analyst Ratings Changes

PCVX has been the topic of a number of recent research reports. Cantor Fitzgerald began coverage on Vaxcyte in a report on Tuesday. They issued an "overweight" rating on the stock. Bank of America lowered their price objective on shares of Vaxcyte from $157.00 to $137.00 and set a "buy" rating on the stock in a research note on Tuesday, April 1st. The Goldman Sachs Group decreased their price target on shares of Vaxcyte from $138.00 to $100.00 and set a "buy" rating on the stock in a research report on Tuesday, April 1st. Guggenheim restated a "buy" rating and issued a $160.00 price objective on shares of Vaxcyte in a research note on Wednesday, March 12th. Finally, Evercore ISI raised Vaxcyte to a "strong-buy" rating in a report on Monday, March 31st. Nine research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $136.50.

Insider Activity at Vaxcyte

In related news, COO Jim Wassil sold 8,000 shares of Vaxcyte stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $86.22, for a total value of $689,760.00. Following the sale, the chief operating officer now directly owns 205,695 shares in the company, valued at approximately $17,735,022.90. The trade was a 3.74 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Over the last quarter, insiders have sold 24,000 shares of company stock worth $1,946,720. 3.10% of the stock is owned by company insiders.

Vaxcyte Price Performance

Vaxcyte stock traded up $0.14 during mid-day trading on Thursday, reaching $33.30. 266,062 shares of the company traded hands, compared to its average volume of 1,226,245. Vaxcyte, Inc. has a fifty-two week low of $27.66 and a fifty-two week high of $121.06. The firm's fifty day moving average is $57.55 and its two-hundred day moving average is $81.39. The company has a market capitalization of $4.29 billion, a price-to-earnings ratio of -7.23 and a beta of 1.26.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last issued its earnings results on Tuesday, February 25th. The company reported ($1.02) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.16) by $0.14. As a group, equities research analysts predict that Vaxcyte, Inc. will post -4.21 earnings per share for the current year.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.